Navigation Links
International collaborative identifies 13 new heart-disease-associated gene sites
Date:3/6/2011

An international research collaboration has identified 13 new gene sites associated with the risk of coronary artery disease and validated 10 sites found in previous studies. Several of the novel sites discovered in the study, which is being published online in Nature Genetics, do not appear to relate to known risk factors, suggesting previously unsuspected mechanisms for cardiovascular disease.

"We now have identifed 23 specific genetic 'letters' that appear to confer risk for myocardial infarction and other aspects of coronary artery disease," says Sekar Kathiresan, MD, director of Preventive Cardiology at Massachusetts General Hospital and one of several co-lead authors of the report. "Knowing these sites lays the groundwork for isolating the genes responsible and developing new treatments based on those genes."

Although inherited factors may account for as much as 60 percent of the variation in risk for coronary artery disease, variants identified in genome-wide association studies (GWAS) account for only a small fraction of that risk. Since some of those previous studies may not have been large enough to identify genes with modest effect, 167 investigators at research centers around the world formed the Coronary ARtery DIsease Genomewide Replication and Meta-analysis (CARDIoGRAM) Consortium.

The researchers first assembled data from 14 previous GWAS for meta-analysis a technique that combines results from several studies into a larger sample which reviewed data from more than 22,000 individual with heart disease and almost 65,000 controls. The most promising sites identifed in the meta-analysis were then genotyped in another group of more than 56,600 individuals, about half with cardiac disease. The investigators also analyzed potential mechanisms and metabolic pathways by which newly identified variants might affect risk.

Results of the analyses confirmed 10 of 12 previously reported gene variants associated with coronary artery disease and identified 13 sites not previously reported. While most of these variants were most strongly associated with early-onset heart disease, the associations did not vary with the actual clinical condition for which patients were treated heart attack or coronary artery disease requiring bypass surgery or angioplasty/stenting. Of the 23 variants validated in this study, seven are associated with LDL cholesterol levels and one with hypertension, but the others have no relation to known cardiovascular risk factors.

"The lack of apparent association with the risk factors we know so well is the source of a lot of excitement concerning these results," Kathiresan explains. "If these variants do not act through known mechanisms, how do they confer risk for heart disease? It suggests there are new mechanisms we don't yet understand. Another good thing about these findings is that they are in human patients, not in cells or mice, which gives us a good starting point for figuring out new disease pathways."


'/>"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. Innovative International Healthcare Partnership established at Arizona State University
2. International Vaccine Institute announces launch of Dengue Vaccine Initiative
3. BUSM researchers involved in first international collaboration on genetics of Alzheimers disease
4. 3rd international conference on innovative approaches in head and neck oncology
5. Lung societies unveil new international classification of lung adenocarcinoma
6. American Chemical Society unveils International Year of Chemistry virtual journal
7. International community called upon to stop the runaway train of cancer in Africa
8. Biodesign hosts international consortium on screening for lung cancer
9. Pier Paolo Pandolfi, M.D., Ph.D., to receive Pezcoller-AACR International Award for Cancer Research
10. International research team reports major findings in prevention and treatment of blood clots
11. International consortium to examine the impact of medical devices on health and retirement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... For additional information contact Phyllis Strupp 480-488-5858 , ... with Age: The Ultimate Guide to Brain Training" by award-winning author Phyllis Strupp ... publication date is March 16, 2016. A free review copy is available to ...
(Date:2/10/2016)... ... February 10, 2016 , ... Everseat has joined ... readily available to physicians. The integration will enable Allscripts users to post open ... Everseat’s free mobile app. , The partnership gives Everseat substantial added power to ...
(Date:2/10/2016)... ... February 10, 2016 , ... Workrite Ergonomics this week announced the launch ... mounts ever. , “Our goal was to develop a product from the ground ... we have ever created.” said Darren Hulsey, Product Manager for Workrite Ergonomics. “The ...
(Date:2/10/2016)... ... ... Anxiety of older Americans over steep cost increases of prescription drugs is at ... to The Senior Citizens League (TSCL). Since last fall, TSCL has ... costs. “The implications are chilling, particularly for people with chronic health problems,” says ...
(Date:2/10/2016)... ... 09, 2016 , ... Ross A. Clevens, MD, FACS ... welcome a new addition to their growing practice. Beginning this month, Teresa Imperiale-Westerfield, ... practitioner performing cosmetic procedures including injectables, fillers and laser treatments. A ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... , February 9, 2016 ... announced a collaboration with 10x Genomics to develop ... single-cell biology and bioinformatics. --> QGEN ... collaboration with 10x Genomics to develop and promote ... and bioinformatics. --> QIAGEN N.V. (NASDAQ: ...
(Date:2/9/2016)... 9, 2016 Mast Therapeutics, Inc. (NYSE ... sickle cell disease and heart failure, today announced that it ... purchase common stock in an underwritten public offering.  The offering ... be no assurance as to whether or when the offering ... terms of the offering.   --> ...
(Date:2/9/2016)... FRANCISCO , February 9, 2016 ... biotechnology company focused on developing products for Regenerative Medicine, ... be a featured presenting company at Source Capital Group,s ... on February 10-11, 2016 in New York ... on Wednesday, February 10, 2016 at 12:30 pm by ...
Breaking Medicine Technology: